Press "Enter" to skip to content

Tag: research

Vaccination Dramatically Lowers Long Covid Risk

At least 200 million people worldwide have struggled with long COVID: a slew of symptoms that can persist for months or even years after an infection with SARS-CoV-2, the virus that causes COVID. But research suggests that that number would likely be much higher if not for vaccines.

A growing consensus is emerging that receiving multiple doses of the COVID vaccine before an initial infection can dramatically reduce the risk of long-term symptoms. Although the studies disagree on the exact amount of protection, they show a clear trend: the more shots in your arm before your first bout with COVID, the less likely you are to get long COVID. One meta-analysis of 24 studies published in October, for example, found that people who’d had three doses of the COVID vaccine were 68.7 percent less likely to develop long COVID compared with those who were unvaccinated. “This is really impressive,” says Alexandre Marra, a medical researcher at the Albert Einstein Israelite Hospital in Brazil and the lead author of the study. “Booster doses make a difference in long COVID.”

Comments closed

Ongoing brain injury caused by COVID-19 may not always be detected by routine tests

A new study published recently in Nature Communications details that markers of brain injury are present in the blood many months after COVID-19 infection, despite inflammation blood tests being normal.

The COVID-CNS study analysed samples from over 800 patients hospitalised with COVID-19 from across England and Wales, half of whom with new neurological conditions. Here researchers measured brain injury markers, serum inflammatory proteins (cytokines), antibodies, and brain (neuroglial) injury proteins.

Comments closed

Less than 5% of US preschool cohort hospitalized for COVID were fully vaccinated, study finds

Only 4.5% of a cohort of pediatric COVID-19 patients admitted to US hospitals during the period of Omicron predominance had completed their primary COVID-19 vaccine series, and 7.0% had started but didn’t finish the series, The Pediatric Infectious Disease Journal reports.

The study team, led by Centers for Disease Control and Prevention (CDC) researchers, enrolled 597 vaccine-eligible COVID-19 inpatients aged 8 months to 4 years at 28 hospitals participating in the Overcoming COVID-19 network from September 2022 to May 2023. A total of 62.1% of patients were aged 8 months to 1 year, and 37.9% were aged 2 to 4 years.

Comments closed

New antibody treatment for RSV in infants highly effective in reducing hospitalisations

A new antibody treatment could reduce by 80 per cent the numbers of babies and young children admitted to hospital with respiratory syncytial virus (RSV), a “groundbreaking” study has found.

Published in the New England Journal of Medicine on Thursday, the study involved 8,058 healthy babies aged up to 12 months from the UK, France and Germany, who were approaching their first RSV season. Half were randomly assigned to receive the antibody nirsevimab by injection, while 4,021 babies received standard care.

Of the babies who received the treatment, only 11 (0.3 per cent) were hospitalised, in comparison with the 60 babies (1.5 per cent) who were hospitalised after receiving just the standard care.

Comments closed

Brain damage caused by COVID-19 may not show up on routine tests, study finds

Our study shows that markers of brain injury are present in the blood months after COVID-19, and particularly in those who have had a COVID-19-induced brain complication (e.g. inflammation, or stroke), despite resolution of the inflammatory response in the blood. This suggests the possibility of ongoing inflammation and injury inside the brain itself which may not be detected by blood tests for inflammation.

Comments closed

COVID-19 linked to a greater risk of Alzheimer’s, other disorders

Another long-term effect of the novel coronavirus appears to be a higher chance of patients contracting Alzheimer’s disease in the years to follow, according to the latest research.

Numerous large research projects overseas have shown a link between COVID-19 and cognitive disorders, along with Alzheimer’s.

“The novel coronavirus is a new risk factor for dementia,” said Takayoshi Shimohata, a neurology professor at Gifu University, who also serves on the health ministry’s editorial committee that compiles a manual for treating COVID-19’s aftereffects. “There needs to be greater understanding that the illness also affects the brain.”

Comments closed

Post-COVID ‘heart failure pandemic’ possible: Japan researchers

After contracting COVID-19, patients may have higher risk of heart failure from persistent viral infection in their hearts, even without developing notable heart disease, according to study results announced by Japanese researchers on Dec. 23.

The team including researchers from Riken, Japan’s largest scientific institute, pointed out the possibility of a “heart failure pandemic” in the near future, and is stressing the need for countermeasures.

Comments closed

Canada enters 5th year of COVID-19. Are we falling short in treatment?

As Canada enters its fifth year navigating COVID-19, some experts and advocates are worried treatment options for the virus remain disappointingly inadequate.

Despite significant strides in understanding the virus, Jennifer Hulme, a 42-year-old emergency physician at the University Health Network in Toronto, says many Canadians suffering from long-term COVID-19 are left without many options.

She is one of them.

Comments closed

コロナ感染、心不全のリスク高まる可能性 理研など研究

On December 23, a research team from Riken and other institutes announced the results of a study showing that after infection with the novel coronavirus, the heart may be persistently infected with the virus and the risk of heart failure may increase, even if the patient does not develop noticeable heart disease. The team points to the possibility of a sharp increase in the number of heart failure patients in the near future and calls for countermeasures to be taken.

Infection with the novel coronavirus occurs when a protruding “spike protein” on the surface of the virus binds to the ACE2 receptor on the surface of human cells. According to the team, the heart is more likely to express ACE2 compared to other organs. It has also been reported that some people infected with the novel coronavirus have reduced cardiac function, but the detailed mechanism is not known.

Comments closed

Long COVID changes heart rate variability, study suggests

According to a small case-control study today in Scientific Reports, long COVID can affect heart rate variability (HRV) at rest and during deep breathing, adding to the evidence that persistent symptoms of the virus can be associated with cardiac and dysfunction of the autonomic nervous system (dysautonomia). This system regulates involuntary functions like heartbeat, blood pressure, and sweating.

The study, conducted by Brazilian researchers, included 21 patients with long COVID and 20 controls. Long COVID—defined by the authors as new or persistent symptoms experienced 12 or more weeks after infection—has been associated with heart palpitations, orthostatic intolerance (difficulty staying upright), dizziness, and syncope.

Comments closed

COVID contact-tracing study suggests length of exposure biggest factor in disease spread

An analysis of 7 million contacts of COVID-19 patients in the United Kingdom estimates that most transmissions resulted from exposures lasting 1 hour to several days and that households accounted for 40% of spread from spring 2021 to early 2022.

Comments closed

Early Paxlovid for COVID-19 halved death, hospitalization in new study

Starting the antiviral drug nirmatrelvir-ritonavir (Paxlovid) 0 or 1 day after COVID-19 symptom onset halved 28-day all-cause death and hospitalization rates compared with waiting 2 or more days, University of Hong Kong researchers report in Nature Communications.

Comments closed

WHO designates JN.1 as separate COVID-19 variant of interest

Due to its rapid growth and potential to add to the respiratory virus burden in Northern Hemisphere countries, the World Health Organization (WHO) today designated JN.1, part of the BA.2.86 SARS-CoV-2 lineage, as its own variant of interest.

The announcement came following an assessment from the WHO’s Technical Advisory Group on SARS-CoV-2 evolution.

Comments closed

This COVID study has been tracking immunity for 3 years. Now it’s running out of money

A long-running study into COVID-19 immunity has unearthed promising insights on the still-mysterious disease, one of its lead researchers says — but she’s concerned its funding could soon dry up.

The Stop the Spread project, a collaboration by the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa, has been monitoring antibody responses to COVID-19 in hundreds of people since October 2020.

Comments closed

Study shows long COVID worse for patients than ‘long flu’

In the 18 months after a serious COVID-19 or seasonal influenza infection, patients are at a significant increased risk of death, hospital readmission, or health problems affecting a number of organs, though COVID patients are hit harder, according to a study published yesterday in The Lancet Infectious Diseases.

The study was led by Ziyad Al-Aly, MD, the chief of research and development at the VA St. Louis Health Care System and a clinical epidemiologist at Washington University. Al-Aly has been studying long COVID for the past 3 years, and has been interested in studying the differences between the acute and chronic phases of the disease.

Comments closed

Many Canadians have had long COVID for almost 4 years. Researchers say there’s hope

Four years ago, Sonja Mally was a busy tattoo artist with a photographic memory and penchant for long hikes.

Now, the 38-year-old Toronto woman considers it a good day if she can do a small drawing, muster the energy to walk around the block or “perform very basic tasks.”

“It’s a hard thing to have to explain to people why maybe one day you might be doing fine and the next day you can’t find the words to complete a sentence,” Mally said.

Comments closed

Le mystère entourant la COVID longue limite les capacités de traitements

Four years after the first cases of what was later called COVID-19, infections continue to spread and lead to new cases of long COVID. However,…

Comments closed

Medicago : Mitsubishi Chemical redonne 40 M $ et transfère la propriété intellectuelle

The Government of Canada has reached an agreement with Mitsubishi Chemical Group Corporation (MCG), Medicago’s parent company. This company will have to pay $40 million in addition to transferring the intellectual property developed by Medicago to the new Quebec company Aramis Biotechnologies.

Comments closed